A carregar...
Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update
SIMPLE SUMMARY: Only 5% of all drug-related targets currently move from preclinical to clinical in cancer, and just some of them achieve patient’s bedside. Among others, intratumor heterogeneity and preclinical cancer model limitations actually represent the main reasons for this failure. Cyclic-AMP...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7693618/ https://ncbi.nlm.nih.gov/pubmed/33126560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113166 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|